

Intarcia Ref. No. INT 004.10
USSN 10/004,118
PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.	
<i>Gary R. Fabian</i>	28 January 2008
Signature	Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: Stanford Mark Moran	Confirmation No. 8022
Serial No.: 10/004,118	Art Unit: 1647
Filing Date: 30 October 2001	Examiner: Seharaseyon, J.
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 and copy of the cited reference accompany this paper.

Applicant request that the Examiner initial and return the form to indicate that the reference has been reviewed and made of record in the present application.


This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

RECEIVED
CENTRAL FAX CENTER Intarcia Ref. No. INT 004.10
JAN 28 2008 USSN 10/004,118
PATENT

Authorization to Charge Deposit Account:

The Commissioner is hereby authorized to charge \$180.00 under 1.17(p) for Submission of an Information Disclosure Statement to Deposit Account No. 504212 (please reference docket number INT 004.10). No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number INT 004.10) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,



Dated: 28 January 2008

By :

Gary R. Fabian, Ph.D.
Agent for Applicant
Registration No. 33,875

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608

01/30/2008 VBUI11 00000007 504212 10004118
02 FC:1806 180.00 DA